Hangzhou Repugene Technology Co., Ltd. is a high-tech advanced biomedical research and development enterprise with the team of Dr. Haigui.
Accurate testing guides accurate diagnosis and treatment | Changan Hospital, Ripgen gene signed agreement, reached a deep strate
Changan looked back and embroidered into piles, and the top of the mountain was opened. With its profound heritage, Chang'an City carries the praise of the literati and the vicissitudes of modern civilization. On December 12, Changan Hospital and Rip Gene and Jiaotong University First Affiliated Hospital jointly established a collaboration meeting in Changan Hospital. In the meeting, Changan Hospital and Rip Gene officially signed a strategic cooperation agreement!
PART1 opening ceremony
The kick-off meeting was presided over by Professor Cui Lichun from Chang'an Hospital. Mr. Yang Jie, Dean of Chang'an Hospital, Professor Li Enxiao of the First Affiliated Hospital of Xi'an Jiaotong University, and Mr. Zhang Long, Director of Rip's Strategy Cooperation Department, delivered the opening speech.
Chang'an Hospital, Yang Jie Dean
In his speech, Dean Yang Jie said that he is very pleased to witness the important strategic cooperation between Changan Hospital and Ripgen Gene. In the era of precision medicine, genetic testing is an important prerequisite for cancer treatment. The Oncology Department of Chang'an Hospital is a key development discipline. We hope that through the establishment of project cooperation, we will improve the level of cancer diagnosis and treatment, create a professional team, and provide individualized precision medicine for patients!
Professor Li Endao, First Affiliated Hospital of Xi'an Jiaotong University
Professor Li Enxiao expressed his wishes and expectations for the signing of cooperation between Changan Hospital and Ripple Gene! In the future, the role of genetic testing in the diagnosis and treatment of cancer will become more and more important. I hope that Ripgen will continue to plow in the field of tumor detection, and closely integrate products with clinical practice to better serve patients!
Mr. Zhang Long, Director of Strategic Cooperation Department of Rip Genetics
Director Zhang Long said that since the establishment of Ripple's gene, it has been adhering to the tenet of “making precision health care into the public”, creating a clinically relevant test product, focusing on the frontier information of tumor diagnosis, researching advanced cutting-edge detection technology, and constantly exploring tumors. New ideas for diagnosis and treatment, and work together with professional technicians to contribute their own strength to the medical cause! Thanks to the support of clinicians, Rip will continue to work hard to bring advanced technology and medical concepts to patients, bringing better clinical benefits and medical benefits to more and more patients!
PART2 "Ancient Covenant" Academic Special Report
Changan Hospital Professor Cui Lichun
Professor Li Endao, First Affiliated Hospital of Xi'an Jiaotong University
21-site addition study
Professor Cui Lichun
With the development of targeted therapy and immunotherapy, the treatment of non-small cell lung cancer has entered a new era. Cancer is no longer simply differentiated from the site of the disease, such as lung cancer, breast cancer, and colorectal cancer, but needs to be redefined based on factors such as histological morphology and biomarkers. The emergence of innovative drugs has changed the mode of cancer treatment, and the treatment has become more rational, standardized, and individualized, and the treatment options are more abundant.
Many previous studies have shown that the efficacy of L858R in NSCLC EGFR routine mutations still needs to be improved. The safe dose range of ectinib is wide, and the double dose has been proven to be well tolerated. The purpose of the INCREASE study is to investigate the double dose and the conventional dose. The difference in efficacy between ectinib and L858R and the tolerance after addition. The study showed that the efficacy of ectinib in the treatment of advanced NSCLC with EGFR21 exon-sensitive mutations was improved and the safety was well tolerated compared with the conventional treatment group. The investigators believe that the high-dose Ecetinib regimen can be considered as a new standard for patients with advanced and metastatic NSCLC EGFR21L858R mutations. Compared with the conventional dose group, the double-dose group prolonged the mPFS by 3.7months, increased the ORR by 25.6%, and was well tolerated.
Seeing NSCLC full management from TKI iteration
Professor Tian Tao
After 20 years of development, lung cancer treatment has undergone earth-shaking changes, from the release/chemotherapy model under the guidance of case staging, to the targeted treatment model under the guidance of driving genes, and then to the precision medicine. The discovery of EGFR gene mutations has enabled the treatment of lung cancer to enter an individualized era. The emergence of multiple generations of EGFR-TKI has created a new problem for clinicians - how should a reasonable array of EGFR-TKI be deployed?
Previous studies have shown that the first-generation EGFR-TKI adverse reactions are quite similar, the second-generation TKI adverse reactions are more serious, and the third-generation TKI adverse reactions are comparable to those of the first generation. In the treatment of patients with brain metastases, the first generation of ectinib and the three generations of octatinib have good effects. Further development of combination therapy may provide new treatment ideas for a generation of TKI. When the second-generation TKI is used in clinical practice, attention should be paid to avoiding toxicity. If the third-generation TKI is the first choice for first-line treatment, it is necessary to pay attention to overcome the problem of drug resistance. Regardless of the TKI priority, clinicians must consider economic factors in order to bring optimal treatment to patients.
NGS gene detection
Dr. Wang Tao
With the continuous development of genetic testing, NGS has become more and more widely used in clinical practice. Currently, it is mainly used for genetic risk screening, targeted therapeutic testing, dynamic monitoring of drug resistance mechanisms, immune library and single cell sequencing, preoperative / Postoperative adjuvant therapy, immunological checkpoint inhibitor testing and other fields. ctDNA liquid biopsy can be applied to the detection of a variety of solid tumors, providing a basis for early diagnosis of tumors, drug resistance mutation mechanism and dynamic monitoring.
Ripgen has a strong research team and has introduced a variety of test products covering lung cancer, ovarian cancer, colorectal cancer, chemotherapy drugs and other different needs in the field of tumor detection, serving and guiding clinicians and patients with precise medication and precise treatment. At present, Ripgen has established in-depth cooperation with Beida Pharmaceutical, Cancer Hospital of Chinese Academy of Medical Sciences, and Cancer Hospital of Tianjin Medical University, and will jointly build testing products suitable for Chinese cancer patients in the future.
After the academic sharing, the guests and the clinicians discussed together, and discussed the clinical application of genetic testing, the selection of clinicians, the clinical research of genetic testing, etc., hoping to be strong through genetic testing companies and hospitals. Jointly, build a reasonable and standardized testing system, produce clinically suitable testing products, help the benign development of China's genetic testing industry, and provide patients with an excellent testing environment.
PART3 unveiling ceremony
During the meeting, Dean Yang Jie of Chang'an Hospital and Mr. Zhang Long, Director of Rip's Genetic Strategic Cooperation Department signed a strategic cooperation agreement. In the future, the Oncology Department of Chang'an Hospital will cooperate with Rip Gene in the field of tumor detection to establish a standardized detection system.
PART4 department visit
After the meeting, Professor Li Xiaoen from the First Affiliated Hospital of Xi'an Jiaotong University, Mr. Zhang Long, Director of Rip Genetic Strategy Cooperation Department, and Dr. Wang Tao, Director of Ripple's Gene Digital Health Department, visited the Department of Oncology of Chang'an Hospital to observe the construction and outpatient department. Happening.